Anti-CTLA-8 / IL-17a Reference Antibody (perakizumab)
- Product Code: 139981
Molecular Weight: | Molecular Formula: | ||
---|---|---|---|
EC Number: | MDL Number: | ||
Melting Point: | Boiling Point: | ||
Density: | Storage Condition: | -20℃ |
Product Description:
Used in the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by specifically binding to interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of these conditions, thereby inhibiting its activity. This reduces inflammation, slows disease progression, and improves clinical symptoms including skin lesions and joint pain. It is administered via subcutaneous injection and is valued for its high specificity and efficacy in patients who do not respond adequately to other biologic therapies.
Sizes / Availability / Pricing:
Size | Availability | Price | Quantity |
---|---|---|---|
50μg | 10-20 days | ฿4,980.00 |
+
-
|
Anti-CTLA-8 / IL-17a Reference Antibody (perakizumab)
Used in the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by specifically binding to interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of these conditions, thereby inhibiting its activity. This reduces inflammation, slows disease progression, and improves clinical symptoms including skin lesions and joint pain. It is administered via subcutaneous injection and is valued for its high specificity and efficacy in patients who do not respond adequately to other biologic therapies.
Mechanism | - |
Appearance | - |
Longevity | - |
Strength | - |
Storage | - |
Shelf Life | - |
Allergen(s) | - |
Dosage (Range) | - |
Recommended Dosage | - |
Dosage (Per Day) | - |
Recommended Dosage (Per Day) | - |
Mix Method | - |
Heat Resistance | - |
Stable in pH range | - |
Solubility | - |
Product Types | - |
INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :